Xiaolan  Guo

Prof. Xiaolan Guo

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
JCJiajing Cai
Jiajing Cai
DWDongsheng Wang
Dongsheng Wang
GZGuoyuan Zhang
Guoyuan Zhang
XGXiaolan Guo
Xiaolan Guo
During the past decade, immunotherapy targeting immune checkpoints has become an important component of the treatment paradigm for numerous malignancies, especially PD-1/PD-L1 blockade which was demonstrated to rejuvenate disabled T cells in cancer patients to achieve long-term remissions. However, the clinical outcome of PD-1/PD-L1 targeted monotherapy against solid malignancies is not satisfactory which may be related with the intricate tumor microenvironment. As a vital suppressive immunocyte in tumor microenvironment, Tregs are characterized by PD-1 and PD-L1 and demonstrated to contribute to the tumor progression. The latest studies have suggested that Tregs might be involved in the treatment of PD-1/PD-L1 blockade and PD-1/PD-L1 axis could influence Treg differentiation and function. However, the complicated relationship between PD-1/PD-L1 pathway and Tregs has not been fully clarified. Here, we explored the role of PD-1/PD-L1 axis in Treg development and function, as well as the potential mechanisms of PD-1/PD-L1 blockade resistance related with Tregs. Meanwhile, we discussed the combination therapy aimed at targeting PD-1/PD-L1 axis and Tregs, hoping to provide novel insights for the future cancer treatment.

26 May 2020 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
QWQiang Wang
Qiang Wang
QDQin Du
Qin Du
BGBin Guo
Bin Guo
DMDaiyong Mu
Daiyong Mu
XLXiaolan Lu
Xiaolan Lu
XGXiaolan Guo
Xiaolan Guo
Objective: To investigate the interference factors that lead to false-positive novel coronavirus (SARS-CoV-2) IgM detected using gold immunochromatography assay (GICA) and enzyme-linked immunosorbent assay (ELISA) and the corresponding solutions. Methods: GICA and ELISA were used to detect SARS-CoV-2 IgM in 86 serum samples, including 5 influenza A virus (Flu A) IgM-positive sera, 5 influenza B virus (Flu B) IgM-positive sera, 5 Mycoplasma pneumoniae IgM-positive sera, 5 Legionella pneumophila IgM-positive sera, 6 sera of HIV infection patients, 36 rheumatoid factor IgM (RF-IgM)-positive sera, 5 sera from hypertensive patients, 5 sera from diabetes mellitus patients, and 14 sera from novel coronavirus infection disease (COVID-19) patients. The interference factors causing false-positive reactivity in the two methods were analyzed, and the urea dissociation test was employed to dissociate the SARS-CoV-2 IgM-positive serum using the best dissociation concentration. Results: Two methods detected positive SARS-CoV-2 IgM in 22 middle-high level RF-IgM-positive sera and 14 sera from COVID-19 patients; the other 50 sera were negative. When urea dissociation concentration was 6 mol/L, SARS-CoV-2 IgM were positive in 1 middle-high level RF-IgM-positive sera and in 14 COVID-19 patient sera detected using GICA. When urea dissociation concentration was 4 mol/L and the avidity index (AI) lower than 0.371 was set to negative, SARS-CoV-2 IgM were positive in 3 middle-high level RF-IgM-positive sera and in 14 COVID-19 patient sera detected using ELISA. Conclusion: Middle-high level of RF-IgM could lead to false-positive reactivity of SARS-CoV-2 IgM detected using GICA and ELISA, and urea dissociation tests would be helpful in reducing false-positive results of SARS-CoV-2 IgM.

24 May 2019 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
QMQiang Ma
Qiang Ma
YXYuan Xu
Yuan Xu
HLHebin Liao
Hebin Liao
YCYan Cai
Yan Cai
LXLei Xu
Lei Xu
XGXiaolan Guo
Xiaolan Guo

9 July 2018 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
FMFang-Yuan Mao
Fang-Yuan Mao
YZYong-Liang Zhao
Yong-Liang Zhao
YLYi-Pin Lv
Yi-Pin Lv
YTYong-Sheng Teng
Yong-Sheng Teng
HKHui Kong
Hui Kong
YZYuan Zhuang
Yuan Zhuang
Myeloid-derived suppressor cells (MDSCs) are a prominent component of the pro-tumoral response. The phenotype of and mechanisms used by MDSCs is heterogeneous and requires more precise characterization in gastric cancer (GC) patients. Here, we have identified a novel subset of CD45+CD33lowCD11bdim MDSCs in the peripheral blood of GC patients compared to healthy individuals. CD45+CD33lowCD11bdim MDSCs morphologically resembled neutrophils and expressed high levels of the neutrophil marker CD66b. Circulating CD45+CD33lowCD11bdim MDSCs effectively suppressed CD8+ T cells activity through the inhibition of CD8+ T cell proliferation and interferon-γ (IFN-γ) and granzyme B (GrB) production. The proportion of CD45+CD33lowCD11bdim MDSCs also negatively correlated with the proportion of IFN-γ+CD8+ T cell in the peripheral blood of GC patients. GC patient serum-derived IL-6 and IL-8 activated and induced CD45+CD33lowCD11bdim MDSCs to express arginase I via the PI3K-AKT signaling pathway. This pathway contributed to CD8+ T cell suppression as it was partially rescued by the blockade of the IL-6/IL-8-arginase I axis. Peripheral blood CD45+CD33lowCD11bdim MDSCs, as well as IL-6, IL-8, and arginase I serum levels, positively correlated with GC progression and negatively correlated with overall patient survival. Altogether, our results highlight that a subset of neutrophilic CD45+CD33lowCD11bdim MDSCs is functionally immunosuppressive and activated via the IL-6/IL-8-arginase I axis in GC patients.

31 August 2019 in BMB Reports
Verified
Journal Article
Open access
PDF file
JZJiang Zou
Jiang Zou
QMQiang Ma
Qiang Ma
RSRu Sun
Ru Sun
JCJiajing Cai
Jiajing Cai
HLHebin Liao
Hebin Liao
XGXiaolan Guo
Xiaolan Guo
Jiang Zou, Qiang Ma, Ru Sun, Jiajing Cai, Hebin Liao, Lei Xu, Jingruo Xia, Guangcheng Huang, Lihua Yao, Yan Cai, Xiaowu Zhong & Xiaolan Guo. BMB Reports 2019;52:520-5. https://doi.org/10.5483/BMBRep.2019.52.8.058

4 March 2017 in BMC Anesthesiology
Verified
Journal Article
Open access
PDF file
XYXiao-Lin Yang
Xiao-Lin Yang
DWDan Wang
Dan Wang
GZGuo-Yuan Zhang
Guo-Yuan Zhang
XGXiaolan Guo
Xiaolan Guo
This study aimed to compare myocardial protective effects of anaesthesia with intravenous infusion of propofol versus inhalation of sevoflurane in patients undergoing heart valve replacement surgery with cardiopulmonary bypass. Seventy-six patients undergoing valve replacement with cardiopulmonary bypass were randomly assigned to propofol or sevoflurane anesthesia during the surgery, respectively. For assessing myocardial injury, cardiac troponin I (cTnI) and creatine kinase isozyme (CK-MB) were determined before induction (T0), 0.5 h (T1) and 3 h (T2) after aortic unclamping, and 24 h (T3) and 48 h (T4) after surgery. The concentrations of interleukin (IL)-6 and IL-10 as the systemic inflammatory and anti-inflammatory markers were also measured at above time points. In the sevoflurane group, the plasma concentrations of cTnI and CK-MB from Tl to T4 and the levels of IL-6 and IL-10 from T1 to T2 were lower than those in the propofol group. Moreover, a higher ratio of automatic heart beat recovery and a shorter length of intensive care unit or hospital stay were found in the sevoflurane group comparing with the propofol group. Sevoflurane anaesthesia produced more prominent myocardial protection and attenuated inflammatory response than propofol anaesthesia in patients with valve replacement surgery under cardiopulmonary bypass, resulting in shorter ICU and in-hospital stay. Identified as ChiCTR-IOR-16009979 at http://www.chictr.org.cn/ .